The positive topline results of our BRIO-I phase 3 pivotal trial evaluating BRIMOCHOL™ PF, our lead investigational candidate for the treatment of #presbyopia, were featured in a recent Ophthalmology Times article. Authors Cecelia Koetting, OD FAAO DipABO and Elizabeth Yeu, MD, noted: “At 1, 2, 4, and 6 hours, Brimochol PF was superior to both carbachol and brimonidine monotherapies, with up to 51% of subjects meeting the preset FDA end point of a ≥ 15-letter gain from predose baseline without a ≥ 5-letter loss.” Link: https://lnkd.in/edpUKZhz
